List view / Grid view

Mantle cell lymphoma (MCL)

Filter the results

 

Mantle cell lymphoma (MCL) is a type of non-Hodgkin’s lymphoma (NHL), comprising about 6% of NHL cases. MCL is a subtype of B-cell lymphoma, due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. MCL cells generally over-express cyclin D1 due to a t(11:14) chromosomal translocation in the DNA. Specifically, the translocation is at t(11;14)(q13;q32).

news

EC approves Revlimid for mantle cell lymphoma

15 July 2016 | By Victoria White, Digital Content Producer

Celgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma...

news

New follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma

10 December 2014 | By Janssen

Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.